Covered recipient · General Payments record
NANCY BROUS-DISTEFANO
Allopathic & Osteopathic Physicians Family Medicine
General Payments · PY2018–2024
$894.95
- Reported across 49 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $283.46 | 17 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Lilly USA, LLC | $83.23 | 5 |
| Acerta Pharma LLC | $54.44 | 3 |
| Amgen Inc. | $45.61 | 3 |
| Phathom Pharmaceuticals, Inc. | $33.78 | 2 |
| EISAI INC. | $21.21 | 1 |
| Exact Sciences Corporation | $15.87 | 1 |
| GlaxoSmithKline, LLC. | $15.15 | 1 |
| Novo Nordisk AS | $14.17 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (17)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Amgen Inc. | $15.82 | 02/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117514749 | CMS |
| Amgen Inc. | $15.38 | 06/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117514751 | CMS |
| Amgen Inc. | $14.41 | 08/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117514753 | CMS |
| AstraZeneca Pharmaceuticals LP | $20.22 | 02/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104482328 | CMS |
| AstraZeneca Pharmaceuticals LP | $19.44 | 06/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105643484 | CMS |
| AstraZeneca Pharmaceuticals LP | $14.78 | 07/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104494664 | CMS |
| Eisai Inc. | $21.21 | 03/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1110769019 | CMS |
| Exact Sciences Corporation | $15.87 | 08/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1114600127 | CMS |
| GlaxoSmithKline, LLC. | $15.15 | 03/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116073673 | CMS |
| Lilly USA, LLC | $16.34 | 03/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135231229 | CMS |
| Lilly USA, LLC | $18.80 | 06/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135278318 | CMS |
| Lilly USA, LLC | $14.28 | 06/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135263690 | CMS |
| Lilly USA, LLC | $18.80 | 07/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135268004 | CMS |
| Lilly USA, LLC | $15.01 | 07/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135268008 | CMS |
| Novo Nordisk Inc | $14.17 | 02/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096944419 | CMS |
| Phathom Pharmaceuticals, Inc. | $16.72 | 05/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1151043684 | CMS |
| Phathom Pharmaceuticals, Inc. | $17.06 | 07/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1151043686 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.